ABSTRACT
El tratamiento con estatinas reduce el riesgo relativo de presentar un episodio coronario en alrededor de un 30%, persistiendo, por lo tanto, un elevado riesgo residual. Hay datos procedentes de estudios epidemiológicos, angiográficos y de intervención que sugieren que el incremento del colesterol unido a lipoproteínas de alta densidad (cHDL) podría reducir el riesgo residual. Aproximadamente, 1 de cada 4 pacientes con cardiopatía isquémica crónica presenta valores de cHDL bajos, independientemente del empleo de estatinas, siendo más frecuentes en mujeres, diabéticos y pacientes con criterios de síndrome metabólico. Por lo tanto, un alto porcentaje de pacientes con cardiopatía isquémica crónica se podría beneficiar de intervenciones dirigidas a elevar el cHDL (AU)
Statin treatment reduces the relative risk of a coronary event by approximately 30% and consequently a high residual risk persists. Data from epidemiological, angiographic and intervention studies suggest that this residual risk could be reduced by increasing highdensity lipoprotein cholesterol (HDL-c). Approximately one out of every four patients with chronic ischemic heart disease has low HDL-c concentrations, independently of the use of statins. In this population low HDL-c levels are most frequent in women, patients with diabetes and those with criteria of metabolic syndrome. Therefore, a high percentage of patients with chronic ischemic heart disease could benefit from interventions aimed at increasing HDL-c levels (AU)
Subject(s)
Humans , Male , Female , Lipoproteins, HDL , Lipoproteins, HDL/metabolism , Biomarkers/metabolism , Coronary Disease/metabolism , Coronary Disease/pathology , Myocardial Ischemia/blood , Diabetes Mellitus/metabolism , Metabolic Syndrome/diagnosis , Lipoproteins, HDL/analysis , Lipoproteins, HDL/classification , Biomarkers/analysis , Coronary Disease/complications , Coronary Disease/diagnosis , Myocardial Ischemia/metabolism , Diabetes Mellitus/diagnosis , Metabolic Syndrome/complicationsABSTRACT
No disponible
Subject(s)
Humans , Vitamin E , beta Carotene , Probucol , Antioxidants , Cardiovascular Diseases , FlavonoidsABSTRACT
Clinical and epidemiological features of intravenous drug addicts (IVDA), who attended the emergency department between 1984 and 1988, were studied. The number of cases treated over these 4 years had increased three-fold (256 vs 724). The median age had increased by 3 years (p less than 0.01). The sex ratio had not changed. A third of the cases knew that they were HIV-seropositive in 1988. The main reason for consultation in 1984 was overdosage and in 1988 it was fever. The rate of admission was similar in both years (around 21%). There was a significant increase in admissions caused by respiratory diseases in 1988 (p less than 0.0001) and a significant decrease of admissions caused by overdosage (p less than 0.001).
Subject(s)
Emergency Service, Hospital , Substance Abuse, Intravenous/epidemiology , Age Factors , Chi-Square Distribution , Drug Overdose/epidemiology , Drug Overdose/etiology , Emergencies , Emergency Service, Hospital/statistics & numerical data , HIV Seropositivity/epidemiology , Heroin/adverse effects , Heroin Dependence/complications , Heroin Dependence/epidemiology , Humans , Retrospective Studies , Sex Factors , Spain , Substance Abuse, Intravenous/complications , Substance Withdrawal Syndrome/epidemiology , Substance Withdrawal Syndrome/etiologyABSTRACT
Vasculitis is a complication happening in a third of patients with primary Sjögren's Syndrome. It can be of 2 types: neutrophilic or mononuclear and sometimes mixed. Very occasionally, a necrotizing vasculitis polyarteritis nodosa type during the evolution of Sjögren's Syndrome has appeared. A case of a female patient with a Sjögren's Syndrome of large evolution, who suddenly showed a poly-systemic affliction (nervous system, kidneys, muscles and digestive system) secondary to a necrotizing vasculitis type polyarteritis nodosa with a good response to immunosuppressors, is presented.
